From Germany: HepaRegeniX hits a kinase that was discovered at the University of Tübingen to regenerate healthy liver cells when inhibited. They already have phase 1b data in hand from the Mayo Clinic
CEO Elias Paptheodorou walks us through the data and descirbes how this has already been tested (for safety) in five cancer patients who had small portions of their liver resected. The next step is to test it in patients with major resections, and also a randomized phase 2a, both of which the company already has the cash to fund.
17 hours ago
From Germany: U.S. listed Immatics was founded in Tubingen and is based on foundational work on PRAME that was done here. A big pivotal is scheduled to read this year
Co-Founder & CEO Harpreet Singh walks us through the science of PRAME, which happened here at the University of Tubingen and led to the work the company does today. A cell therapy program in melanoma will have a pivotal read this year, and Immatics also has bispecific programs and a second generation cell therapy under development.
20 hours ago
Unnatural Products has built its expertise in developing macrocyclic peptides. It had already landed four major partnerships before raising its series B in March
Co-Founder & CEO Cameron Pye walks us through the science of macrocyclic peptides, and discusses the for partnerships (BridgeBio, argenx, Merck, and Novartis). The company raised a $45M series B in March.
4 days ago
Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process
Philip Astley-Sparke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
6 days ago
Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases. Chapters His career - 0:00 A monoclonal approach - 1:50 Measles - 7:28 The science behind Invivyd - 11:10 Pandemic preparedness - 19:24 Advice to students - 20:50
6 days ago
Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip
Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such a system could also improve a patient's rehab and might potentially have further uses in diseases of cognitive decline.
7 days ago
.png){kind=logo}
